Navigation Links
Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide
Date:11/25/2013

DUBLIN, November 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/q99tkv/ziopharm) has announced the addition of the "Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The rationale to develop a stable formulation of palifosfamide is strong: it is the active metabolite of ifosfamide, a well-established alkylating chemotherapy agent. Palifosfamide may spare patients from the toxicities of two other inactive ifosfamide metabolites while retaining its anti-tumor activity. A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year. In this report, we review the evidence supporting palifosfamide's development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.

Key Topics Covered:

INTRODUCTION

1. Sarcomas
2. Treatment and prognosis of soft tissue sarcoma
3. Treatment of advanced or metastatic soft tissue sarcoma



PALIFOSFAMIDE

1. Palifosfamide as a single-agent
2. Palifosfamide in combination with doxorubicin
3. Phase I
4. Phase II
5. On-going phase III
6. Phase III trial in small cell lung cancer



CLINICAL AND REGULATORY OPINION

1. The rationale supporting the development of palifosfamide
2. Ifosfamide is active in STS: what does this mean for palifosfamide?
3. Phase II trial of palifosfamide suggests antitumor activity
4. Palifosfamide offers a better safety profile than ifosfamide
5. Ziopharm initiate PICASSO III pivotal trial without FDA's SPA
6. The two regulatory approval pathways
7. Is palifosfamide eligible for Accelerated Approval?
8. Is PFS a validated surrogate for overall survival in randomized front-line STS cancer trials?
9. The Votrient Precedent - Full approval based on PFS
10. Will palifosfamide succeed in the PICASSO III trial?
11. Is the MATISSE phase III trial in SCLC likely to succeed?


MARKET OPPORTUNITY

1. Revenue projection in STS
2. Revenue projections in other indications
3. Competitive landscape



CONCLUSION

Companies Mentioned


- Threshold Pharmaceuticals
- Merck KgaA
- Eisai
- Zeltia
- JNJ
- Ariad Pharmaeuticals,Glaxo-Smith Kline



For more information visit http://www.researchandmarkets.com/research/q99tkv/ziopharm

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
2. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
3. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
4. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
5. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
6. Long Term Follow Up Data On WEB Aneurysm Embolization System Demonstrate High Rate Of Stable Occlusion In Difficult To Treat Aneurysms
7. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
10. Maximum-Strength Formulation Offers Highest Concentration and Purity
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WASHINGTON , May 26, 2016 ... Microspheres, Associated With Both Cost Savings and ... BTG plc (LSE: BTG), an international specialist healthcare ... data at the 21st Annual Meeting of ISPOR ... that treatment of hepatocellular carcinoma (HCC) using yttrium-90 ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, ... public. , Dr. Maisel, founder of Retina Group of New York , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps ... from daily practices, arts & crafts, discussions, and games all geared towards enhancing ... Evans have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global ...
Breaking Medicine News(10 mins):